(Circulation. 1999;100:1521-1527.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Departments of Cardiology (G.V., O.O., B.D., J.M.) and Nuclear Medicine (D.F., M.C.), University Hospital, Grenoble, France.
Correspondence to Dr Gérald Vanzetto, Clinique Cardiologique, CHU de Grenoble, BP 217, 38043 Grenoble, Cedex 9, France. E-mail Gerald.Vanzetto{at}ujf-grenoble.fr
| Abstract |
|---|
|
|
|---|
Methods and ResultsOne thousand one hundred thirty-seven
patients (857 men, age 55±9 years) referred for typical (62.1%) or
atypical (22.4%) chest pain, or suspected silent ischemia
(15.5%), were followed up for 72±18 months. Overall mortality was
higher after strongly positive (ST depression >2 mm, or >1
mm for a workload
75 W) (2.36%/y) or nondiagnostic ETT
(1.63%/y) than after normal (0.85%/y) or positive ETT (1.37%/y)
(P=0.002), and after abnormal SPECT than after normal
SPECT (1.60%/y versus 0.68%/y, P=0.001). The
major cardiac event rate (cardiac death or myocardial infarction
[MI]) was 0.88%, 1.59%, 2.10%, and 2.13%/y after negative,
positive, strongly positive, and nondiagnostic ETT,
respectively (P=0.003), and 0.56%, 1.43%, and 2.05%/y
in patients with 0, 1 to 2, and
3 abnormal segments on SPECT,
respectively (P<0.002). An abnormal SPECT was
predictive of MI (P<0.001), whereas ETT was not. In
multivariate analysis, SPECT was of incremental
prognostic value over clinical and ETT data for predicting overall
mortality and major cardiac events.
ConclusionsThe incremental predictive value of SPECT is maintained over 6 years and is particularly relevant after positive, strongly positive, and nondiagnostic ETT.
Key Words: coronary disease prognosis exercise scintigraphy
| Introduction |
|---|
|
|
|---|
The aim of our study was therefore to assess, in a large cohort of patients with low- to intermediate-likelihood of future cardiac events, whether the prognostic value of Tl201-SPECT was maintained at long-term follow-up and whether myocardial perfusion imaging was of incremental prognostic value over clinical and ETT data.
| Methods |
|---|
|
|
|---|
ETT
Patients performed a symptom-limited ETT on an ergometer bicycle
using a standard protocol.13 Patients were asked to
discontinue anti-ischemic drugs at least 48 hours before
the test.
A semi-quantitative treadmill score was derived, with ETT being
considered as (1) positive: horizontal or downsloping ST segment
depression of 1 to 2 mm measured 0.08 second after the J point,
occurring for a workload >75 W, with or without chest pain; (2)
strongly positive: ST segment depression >2 mm at any workload,
or >1 mm for a workload
75 W, or ST depression post
exercise duration >6 minutes; (3) negative: when ST segment remained
isoelectric and heart rate achieved
85% of maximum age-predicted
heart rate; and (4) nondiagnostic in all other cases.
Tl201-SPECT
Stress-redistribution Tl201-SPECTs were performed according to a
standard protocol as previously reported.13 After
normalization to the pixel with maximum activity, the reconstructed
SPECT images were displayed in standard fashion as short axis,
horizontal axis, and vertical axis slices using a 256 color scale with
normal areas (in red) corresponding to a Tl201 uptake >75% of maximum
activity. The left ventricle was divided into 6 segments to enable
comparison with the results obtained in our previous
report,13 and images were visually analyzed by 2
experts. A segment was scored as abnormal in the event of decreased
tracer uptake in a surface large enough to be considered significant by
the experts. Abnormal segments were defined as reversible (partial or
total normalization on redistribution imaging) or fixed.
Data Collection and End Points of the Study
Follow-up was obtained from the patients and their cardiologists
using written questionnaires and telephone contacts, when necessary. If
no response was obtained, an inquiry was performed with the civil
authorities. End points were: (1) overall mortality; (2) cardiac
mortality (sudden death or death of demonstrated cardiac origin);
(3) occurrence of MI (on the basis of characteristic chest pain,
ECG changes, and serum creatinine kinase level >
twice the upper limit of normal value); (4) need for myocardial
revascularization >3 months after Tl201-SPECT,
based on occurrence of severe angina, unstable angina, or acute MI.
Major cardiac events were defined by the occurrence of cardiac death or
MI.
Statistical Analysis
Variables were expressed as mean value ±1SD or number (%)
and compared using Student's unpaired t test or a Pearson
2 test. Survival curves were
traced on SPSS software using the Kaplan-Meyer method and compared
using a log-rank test. When more than 1 event occurred in a patient,
only the most severe event was considered in the survival
analysis. Annual event rates were calculated by dividing the
event rates at the end of follow-up by the mean duration of follow-up.
Univariate and multivariate stepwise
analyses using a Cox regression model were performed to compare
the prognostic value of clinical, ETT, and Tl201-SPECT data.
P value <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
During follow-up (72±18 months [11 days to 8 years]), 88 patients (7.7%) died, 46 (4%) from a cardiac cause and 42 (3.7%) from a noncardiac cause. MI occurred in 57 patients (5.0%), 7 of whom died from a cardiac cause 8±4 months later. A total of 136 patients (12%) underwent myocardial revascularization (PTCA [n=63] and/or CABG [n=80]) 24±26 months after inclusion in the study.
At the end of follow-up, 273 patients were receiving ß-blockers, 182 were receiving calcium antagonists, and 682 (60%) had neither of these treatments (547 after normal ETT and normal or mildly abnormal SPECT, 62 after myocardial revascularization, and 73 despite the presence of significant ischemia on initial tests). All patients received advice for optimal eradication of risk factors. Major cardiac events and any cardiac event rates were 1.51% and 3.40%/y, respectively.
Univariate Predictors of Events
Overall Mortality
Age >60 years, previous history of MI, ETT, and Tl201-SPECT were
predictors of overall mortality (Figures 1
and 2
).
The mortality rate was higher after a strongly positive
(2.36%/y) or nondiagnostic ETT (1.63%/y) than after a
negative (0.85%/y) or positive ETT (1.37%/y) (P=0.002),
and after an abnormal (1.60%/y) than after a normal (0.68%/y)
Tl201-SPECT (P=0.001). In patients who survived the first 3
years of follow-up, the relationship between the results of the tests
and the occurrence of death was maintained for Tl201-SPECT
(P=0.01) but not for ETT.
|
|
Major Cardiac Events
Gender, previous history of MI, presence of >1 risk factor, ETT,
and Tl201-SPECT were predictors of major cardiac events. The respective
major cardiac event rate was 0.88%, 1.59%, 2.10%, and 2.13%/y after
normal, positive, strongly positive, and nondiagnostic ETT
(P=0.003), and 0.56%, 1.43%, and 2.05%/y in patients with
0, 1 to 2, and
3 abnormal segments, respectively, on Tl201-SPECT
(P<0.002) (Figure 3
). In
patients free of events during the first 3 years, the value of ETT and
Tl201-SPECT for the prediction of future major cardiac events was
preserved (P=0.009 and 0.002, respectively).
|
Predictors of cardiac death and MI are summarized in Table 2
. The cardiac mortality rate was higher
after a strongly positive or a nondiagnostic ETT than after
a positive or a negative ETT (1.18% and 1.10% versus 0.44% and
0.37%/y, P=0.02), and after an abnormal than after a normal
Tl201-SPECT (0.87% versus 0.30%/y, P=0.006), with a
significant relationship between the number of abnormal segments and
the occurrence of future cardiac death (Figures 4
and 5
).
|
|
|
The MI rate was 0.51%/y after a normal ETT and nonsignificantly higher
after a positive, strongly positive, or nondiagnostic ETT
(1.33%, 1.05%, and 1.15%/y, respectively, P=0.12).
Conversely, Tl201-SPECT was highly predictive of future MI (0.25% and
1.13%/y after normal and abnormal Tl201-SPECT, respectively,
P=0.001): the greater the defect, the higher the MI rate
(Figure 5
).
Fixed defects were associated with a higher risk of future cardiac death (6.7% versus 2.6% in patients without fixed defects, P=0.03) whereas reversible defects were more predictive of future MI (6.9% versus 4.0% in patients without reversible defects, P=0.03).
Myocardial Revascularization
The revascularization rate was 1.21%, 4.28%,
3.02%, and 2.01%/y after normal, positive, strongly positive, and
nondiagnostic ETT, respectively (P<0.001).
Similarly, revascularization was more frequent
after abnormal than after normal Tl201-SPECT (2.65% versus 0.60%/y,
P<0.0001), especially in the presence of
1 reversible
defect (2.86% versus 1.51%/y, P<0.0001) or of a large
defect (Figure 5
).
Multivariate Predictors of Events
Age (P=0.04), ETT (P=0.03), and Tl201-SPECT
(P=0.003) were independent predictors of overall mortality.
Multivariate predictors of major cardiac events are
summarized in Table 3
: Tl201-SPECT and
ETT were independent predictors of cardiac death. Tl201-SPECT was also
predictive of future MI, whereas ETT was not. Figure 6
depicts the incremental prognostic
value of clinical, ETT, and Tl201-SPECT data considered in hierarchical
order.
|
|
| Discussion |
|---|
|
|
|---|
Long-Term Prognostic Value of Myocardial Perfusion Imaging
The short- to medium-term prognostic value of myocardial perfusion
imaging is established: after normal scan, the major cardiac event rate
is <1%/y during the 1 to 3 years following
examination.6 7 8 13 Conversely, the greater the perfusion
defect, the higher the likelihood of future events.6 7 13
Fixed defects reflect the amount of irreversibly injured
myocardium and left ventricular dysfunction and
are more predictive of future deaths, whereas reversible defects
reflect the amount of jeopardized myocardium and are more
predictive of future ischemic events.11 17
Furthermore, a large perfusion defect (>40% of the
myocardium) is a powerful predictor of mortality, whereas
patients with mild to moderate defect size (15% to 35% of the
myocardium) have a higher likelihood of future
MI.18 These conclusions, however, have been drawn from
medium-term follow-up studies (21 to 44
months)6 11 13 15 18 or from long-term follow-up studies
(6 to 10 years) on relatively small populations (217 to 309 patients)
of selected patients with normal perfusion scans19 or
documented CAD.20 21
In this study, the prognostic value of Tl201-SPECT was maintained over a 6-year period in a population of 1137 patients with relatively low likelihood of events, extending the conclusions drawn from our 33-month follow-up study13 and from other short- to medium-term studies6 7 8 9 10 11 12 : the major cardiac event rate remained remarkably low after normal perfusion scan and was 3.3 times higher after an abnormal scan, with a close relationship between the extent of perfusion abnormalities and the occurrence of events.
The major cardiac event rate in our population was relatively low (1.51%/y), compared with 3.0%/y in a population with a higher rate of previous MI or ischemic events,18 and 1.19%/y in a population of patients without known CAD.17 Although a high number of patients were studied for angina, 70% of our patients had no previous serious ischemic events and none had a history of recent MI. Our patients were also 8 years younger than those in the previous studies.17 18 Furthermore, the major cardiac event rate in middle-aged Frenchmen has been reported to be 1.56 to 2.24 times lower than in the US population.23 Nevertheless, we confirmed in this setting that (1) the occurrence of major cardiac events was dramatically increased in patients with a large perfusion defect; (2) a mild to moderate defect was a predictor of future MI18 ; (3) a fixed defect was a long-term predictor of death; and (4) a reversible defect predicted further ischemic events.
Survival curves continued to diverge over time, suggesting that the predictive value of Tl201-SPECT was maintained over 6 years: patients with abnormal scans who survived the first 3 years had an impaired long-term prognosis, whereas there was no inflection in the survival curve of patients with normal tests.
Additive Value of Tl201 Perfusion Imaging Over Clinical and
ETT Data
Several studies have demonstrated the medium-term additive value
of perfusion imaging over clinical and ETT data in populations with
high,14 intermediate,15 16 18
low,17 or very low24 likelihood of CAD. At
long-term follow-up, we found that a negative ETT conferred a better
prognosis than a strongly positive or nondiagnostic ETT and
that ETT was of incremental value over clinical data despite its
suboptimal negative predictive value. Tl201 scan provided long-term
incremental value over clinical and ETT data (Figure 7
), consistent with the study by
Nallamothu et al, demonstrating that SPECT was superior to ETT for
identifying patients with extensive CAD.25 Because
perfusion imaging better reflects the extension of CAD than does ETT,
it is logical that the long-term prognostic information provided by
Tl201-SPECT will be of incremental value over that afforded by ETT.
|
Limitations of the Study
A quantitative treadmill score was not used in our study, as its
value was not clearly demonstrated at the start of our
survey.4 However, we used a semiquantitative 4-grade
score, taking into account parameters acknowledged to be of
prognostic value.26 Another possible limitation is the
absence of quantitative analysis for SPECT scans. However,
expert visual analysis has recently been demonstrated to be
similar to automatic quantitative analysis for prognostic
stratification.27 Finally, the Tl-201 heart to lung uptake
ratio was not available for our patients.
Myocardial revascularization was performed in 102 patients without subsequent events: the prognostic accuracy of ETT and Tl201-SPECT might therefore have been underestimated rather than overestimated in these patients. A posthoc analysis excluding these patients did not, however, alter our results. Furthermore, revascularization was performed less frequently in our series than in more recent studies,18 because guidelines now recommend that patients with a large perfusion defect undergo myocardial revascularization.28 Similarly, the use of ß-blockers might have improved the prognosis of patients with abnormal tests but these biases would have affected both ETT and Tl201-SPECT to the same extent.
Conclusions and Clinical Implications
Myocardial perfusion imaging is of long-term prognostic value in
patients with low-to intermediate likelihood of CAD, patients with
normal Tl201-SPECT having a very low probability of future major
cardiac events. The incremental prognostic value of Tl201-SPECT over
clinical and ETT data are particularly relevant, after positive,
strongly positive, and nondiagnostic ETT, our results
suggesting that, in this setting, patients with normal scans do not
require further explorations for the 6 years following initial
examination.
Received March 5, 1999; revision received June 18, 1999; accepted June 28, 1999.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Y. Chan, H.-B. Wong, H.-Y. Ong, and T.-C. Yeo Prognostic value of left atrial size in chronic kidney disease Eur J Echocardiogr, March 20, 2008; (2008) jen131v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. H.J. Pijls, P. van Schaardenburgh, G. Manoharan, E. Boersma, J.-W. Bech, M. van't Veer, F. Bar, J. Hoorntje, J. Koolen, W. Wijns, et al. Percutaneous Coronary Intervention of Functionally Nonsignificant Stenosis: 5-Year Follow-Up of the DEFER Study J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2105 - 2111. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Navare, J. F. Mather, and G. V. Heller Reply J. Am. Coll. Cardiol., October 3, 2006; 48(7): 1472 - 1473. [Full Text] [PDF] |
||||
![]() |
K. Yoshinaga, B. J.W. Chow, K. Williams, L. Chen, R. A. deKemp, L. Garrard, A. Lok-Tin Szeto, M. Aung, R. A. Davies, T. D. Ruddy, et al. What is the Prognostic Value of Myocardial Perfusion Imaging Using Rubidium-82 Positron Emission Tomography? J. Am. Coll. Cardiol., September 5, 2006; 48(5): 1029 - 1039. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Berman, R. Hachamovitch, L. J. Shaw, J. D. Friedman, S. W. Hayes, L. E.J. Thomson, D. S. Fieno, G. Germano, N. D. Wong, X. Kang, et al. Roles of Nuclear Cardiology, Cardiac Computed Tomography, and Cardiac Magnetic Resonance: Noninvasive Risk Stratification and a Conceptual Framework for the Selection of Noninvasive Imaging Tests in Patients with Known or Suspected Coronary Artery Disease J. Nucl. Med., July 1, 2006; 47(7): 1107 - 1118. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Pellegrino, G. Storto, P. P. Filardi, A. R. Sorrentino, A. Silvestro, M. Petretta, G. Brevetti, M. Chiariello, M. Salvatore, and A. Cuocolo Relationship Between Brachial Artery Flow-Mediated Dilation and Coronary Flow Reserve in Patients with Peripheral Artery Disease J. Nucl. Med., December 1, 2005; 46(12): 1997 - 2002. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J.W. Chow, J. W. Wong, K. Yoshinaga, T. D. Ruddy, K. Williams, R. A. deKemp, J. DaSilva, and R. S. Beanlands Prognostic Significance of Dipyridamole-Induced ST Depression in Patients with Normal 82Rb PET Myocardial Perfusion Imaging J. Nucl. Med., July 1, 2005; 46(7): 1095 - 1101. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. S. Valeti, T. D. Miller, D. O. Hodge, and R. J. Gibbons Exercise Single-Photon Emission Computed Tomography Provides Effective Risk Stratification of Elderly Men and Elderly Women Circulation, April 12, 2005; 111(14): 1771 - 1776. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Mieres, L. J. Shaw, A. Arai, M. J. Budoff, S. D. Flamm, W. G. Hundley, T. H. Marwick, L. Mosca, A. R. Patel, M. A. Quinones, et al. Role of Noninvasive Testing in the Clinical Evaluation of Women With Suspected Coronary Artery Disease: Consensus Statement From the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association Circulation, February 8, 2005; 111(5): 682 - 696. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Liao, W. T. Smith IV, R. H. Tuttle, L. K. Shaw, R. E. Coleman, and S. Borges-Neto Prediction of Death and Nonfatal Myocardial Infarction in High-Risk Patients: A Comparison Between the Duke Treadmill Score, Peak Exercise Radionuclide Angiography, and SPECT Perfusion Imaging J. Nucl. Med., January 1, 2005; 46(1): 5 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Itti, G. Klein, J. Rosso, E. Evangelista, J.-L. Monin, P. Gueret, M. Meignan, and J.-P. Thirion Assessment of Myocardial Reperfusion After Myocardial Infarction Using Automatic 3-Dimensional Quantification and Template Matching J. Nucl. Med., December 1, 2004; 45(12): 1981 - 1988. [Abstract] [Full Text] [PDF] |
||||
![]() |
S L Rahman and A D Kelion Nuclear cardiology in the UK: do we apply evidence based medicine? Heart, August 1, 2004; 90(suppl_5): v37 - v40. [Full Text] [PDF] |
||||
![]() |
A. Sultan, C. Piot, D. Mariano-Goulart, M. Rasamisoa, E. Renard, and A. Avignon Risk Factors for Silent Myocardial Ischemia in High-Risk Type 1 Diabetic Patients Diabetes Care, July 1, 2004; 27(7): 1745 - 1747. [Full Text] [PDF] |
||||
![]() |
S. Borges-Neto, R. H. Tuttle, L. K. Shaw, W. T. Smith IV, D. Jain, R. E. Coleman, and D. Whellan Outcome Prediction in Patients at High Risk for Coronary Artery Disease: Comparison between 99mTc Tetrofosmin and 99mTc Sestamibi Radiology, July 1, 2004; 232(1): 58 - 65. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Giedd and S. R. Bergmann Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis, disease progression, and directed reintervention J. Am. Coll. Cardiol., February 4, 2004; 43(3): 328 - 336. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Beller and D. D. Watson Risk stratification using stress myocardial perfusion imaging: don't neglect the value of clinical variables J. Am. Coll. Cardiol., January 21, 2004; 43(2): 209 - 212. [Full Text] [PDF] |
||||
![]() |
N K Sabharwal and A Lahiri Role of myocardial perfusion imaging for risk stratification in suspected or known coronary artery disease Heart, November 1, 2003; 89(11): 1291 - 1297. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. L. Schinkel, A. Elhendy, R. T. van Domburg, J. J. Bax, R. Valkema, J. R. T. C. Roelandt, and D. Poldermans Long-term Prognostic Value of Dobutamine Stress 99mTc-Sestamibi SPECT: Single-Center Experience with 8-year Follow-up Radiology, December 1, 2002; 225(3): 701 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. J. Chamuleau, R. A. Tio, C. C. de Cock, E. D. de Muinck, N. H. J. Pijls, B. L. F. van Eck-Smit, K. T. Koch, M. Meuwissen, M. G. W. Dijkgraaf, A. de Jong, et al. Prognostic value of coronary blood flow velocity and myocardial perfusion in intermediate coronary narrowings and multivessel disease J. Am. Coll. Cardiol., March 6, 2002; 39(5): 852 - 858. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Th. Wackers and B. L. Zaret Detection of Myocardial Ischemia in Patients With Diabetes Mellitus Circulation, January 1, 2002; 105(1): 5 - 7. [Full Text] [PDF] |
||||
![]() |
F. Harel, R. Genin, D. Daou, R. Lebtahi, N. Delahaye, B. O. Helal, D. Le Guludec, and M. Faraggi Clinical Impact of Combination of Scatter, Attenuation Correction, and Depth-Dependent Resolution Recovery for 201Tl Studies J. Nucl. Med., October 1, 2001; 42(10): 1451 - 1456. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.C. Allman and L.E.J. Thomson Prognostic value of myocardial perfusion imaging in patients with known or suspected coronary artery disease Eur. Heart J. Suppl., September 1, 2001; 3(suppl_F): F5 - F7. [Abstract] [PDF] |
||||
![]() |
S. T. Mast, L. K. Shaw, G. C. Ravizzini, M. Chambless, P. Joski, R. E. Coleman, and S. Borges-Neto Incremental Prognostic Value of RNA Ejection Fraction Measurements During Pharmacologic Stress Testing: A Comparison with Clinical and Perfusion Variables J. Nucl. Med., June 1, 2001; 42(6): 871 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
B Haluska, C Case, L Short, J Anderson, and T H Marwick Effect of power Doppler and digital subtraction techniques on the comparison of myocardial contrast echocardiography with SPECT Heart, May 1, 2001; 85(5): 549 - 555. [Abstract] [Full Text] |
||||
![]() |
D.R. Holdright The role of pharmacological stress echo for evaluating chest pain in women Eur. Heart J., January 2, 2001; 22(2): 107 - 109. [PDF] |